Skip to main content

Psoriasis clinical trials at UCSF

5 in progress, 4 open to eligible people

Showing trials for
  • Guselkumab Immunogenetics

    open to eligible people ages 18 years and up

    This is a two-arm open-label study to evaluate the clinical and immunogenetic responses of patients with plaque or guttate psoriasis to treatment with guselkumab.

    San Francisco, California

  • Immunogenetic Profiling of Goeckerman Therapy in the Treatment of Psoriasis Vulgaris

    open to eligible people ages 18 years and up

    This study examines the effect of Goeckerman therapy (a combination of phototherapy and topical crude coal tar), crude coal tar alone, and phototherapy alone on the immunologic and genetic environment within psoriatic skin lesions.

    San Francisco, California

  • Light Treatment Effectiveness (LITE) Study

    open to eligible people ages 12 years and up

    To compare the effectiveness, safety (tolerability), and duration of treatment response at 12 weeks of home versus office-based narrowband ultraviolet B phototherapy for the treatment of psoriasis

    San Francisco, California and other locations

  • Predicting Inflammatory Skin Disease Response to IL-23 Blockade

    open to eligible people ages 18 years and up

    This study examines the effect of IL-23 blockade with Tildrakizumab on the immune cells of psoriatic skin lesions.

    San Francisco, California

  • Chronic Plaque Psoriasis (Ps) Registry

    Sorry, in progress, not accepting new patients

    The purpose of this study is to evaluate the long-term safety of Humira® in Adult Patients with Chronic Plaque Psoriasis (Ps).

    San Francisco, California and other locations

Last updated: